Browse recruiting and upcoming clinical trials for progressive supranuclear palsy.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIPeople aged 41–81 with mild–moderate probable or possible Progressive Supranuclear Palsy Richardson syndrome (PSP‑RS) with symptom onset <5 years.
What is being studied AITests whether NIO752 affects clinical scores, biomarkers, MRI measures, and safety versus placebo.
Who can join AIPeople with Parkinson's disease or related movement disorders, including progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, vascular Parkinsonism, orthostatic tremor, dystonia, and tremor disorders.
What is being studied AITests feasibility, safety, tolerability, and effects of the CUE1/CUE1+ wearable device on symptoms.
Who can join AIAdults aged 30–85 with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal syndrome (CBS) who meet the study's diagnostic and testing requirements.
What is being studied AITests whether daily nicotinamide riboside affects disease progression and symptoms in atypical parkinsonism.
Who can join AIPeople with primary tauopathies, including Progressive Supranuclear Palsy (PSP non‑RS), Corticobasal Degeneration (CBS non‑AD), and MAPT‑related frontotemporal lobar degeneration.
What is being studied AIEvaluates safety, tolerability, and pharmacodynamics of NIO752 versus placebo in primary tauopathies.
Who can join AIHealthy adults and people with Alzheimer dementia, ALS, Parkinson's or related movement disorders, DLB, or adult/very-late-onset psychotic disorders.
What is being studied AIUltra‑high‑resolution PET and MRI scans with multiple tracers to image small brain and spinal cord regions.
Who can join AIPeople with FTLD-spectrum diseases (bvFTD, PPA, PSP, CBS, ALS), people with genetic FTLD or related family members, and healthy controls.
What is being studied AIMaps and models brain network changes and protein spreading using MRI, CSF, and genetic data.
Who can join AIPeople with age-related or inherited neurodegenerative conditions (for example AD, PD, FTD, ALS, DLB), their family members, and healthy controls.
What is being studied AICollects and banks blood, DNA/RNA, and clinical and family history data for neurodegenerative research.
Who can join AIPeople aged 50–75 with Parkinson disease or related parkinsonian syndromes (PD, MSA, PSP, CBD, DLB, vascular or drug‑induced parkinsonism).
What is being studied AITests AI-analyzed motor recordings with levodopa challenge to find diagnostic cut-offs and digital biomarkers.
Who can join AIAdults (age 35 or older) with PSP, corticobasal syndrome/degeneration (CBS/CBD), or multiple system atrophy (MSA), and unaffected family members of affected people.
What is being studied AICollects blood for research whole-genome sequencing and confirms possibly related findings with CLIA testing.
Who can join AIPeople with neurodegenerative diseases or cognitive impairment (e.g., Parkinson disease, Alzheimer disease, Lewy body disease, MSA, ALS).
What is being studied AICollects clinical, movement, imaging, EEG, voice, microbiota, and blood data for marker discovery.
Who can join AIPeople aged 30 days or older who have one of the listed conditions (for example ALS, Alzheimer disease, Parkinson disease, MS, diabetes, certain reproductive cancers, or PTSD) or who serve as healthy controls.
What is being studied AICollects blood, skin, and saliva to make stem cells, run genetic tests, and store samples.
Who can join AIAdults with various neurodegenerative diseases, people with a family history of these diseases, and adults without neurological disease as controls.
What is being studied AICollects clinical, cognitive, speech, imaging, genetic and biofluid data for neurodegenerative disease research.
Who can join AIAdults (18+) with neurodegenerative diseases, including MSA, Parkinson disease, PSP, motor neuron disease, or other neurodegenerative disorders.
What is being studied AICollects FEES laryngeal exam results, laryngeal EMG if available, and swallowing questionnaires.
Who can join AIPeople with frontotemporal lobar degeneration syndromes (for example bvFTD, svPPA, nfvPPA, PSP, CBD, FTD/ALS, ALS), or members of families with a known FTLD gene mutation or a strong family history of FTLD.
What is being studied AICollects clinical data, brain imaging, and biosamples to track FTLD over time.
Who can join AIAdults with frontotemporal dementia, amyotrophic lateral sclerosis, progressive supranuclear palsy, or related adult-onset neurodegenerative disorders.
What is being studied AICollects clinical data, imaging and biospecimens to characterize ALS-FTD spectrum disorders.
Who can join AIPeople with PSP, corticobasal syndrome, behavioral variant FTD, semantic or non‑fluent PPA, FTD‑motor neuron disease, or healthy control volunteers.
What is being studied AIBrain imaging, skin biopsy, blood and CSF samples, cognitive and functional testing.
Who can join AIPeople diagnosed with atypical parkinsonian syndromes: Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), or Corticobasal Degeneration (CBD).
What is being studied AITracks symptom progression and clinical/biomarker changes in atypical parkinsonian syndromes over three years.
Who can join AIPeople aged 30–95 with mild cognitive impairment or early-stage dementia from neurodegenerative diseases (e.g., Alzheimer's, Lewy body, vascular, frontotemporal).
What is being studied AICollects MRI, blood, CSF, skin biopsy, cognitive tests, and questionnaires to model disease progression.
Who can join AIPeople with neurodegenerative diseases (Parkinson disease, multiple system atrophy, progressive supranuclear palsy, Alzheimer's disease, motor neuron disease, small vessel disease, frontotemporal dementia) and healthy controls.
What is being studied AICollects clinical data, questionnaires, cognitive scores and blood samples for biomarker research.